Company intelligence / Profile preview

Agyany Pharma

Ownership: Private
Development stage: Preclinical

Overview

Agyany is developing treatments for Parkinson's disease, focusing on ambroxol as a pharmacological chaperon for GBA1-related Parkinson's. The company plans to begin clinical trials in newly diagnosed PD patients using existing generic drugs, aiming to provide a shorter path to novel therapeutic approaches for both GBA-related PD and potentially idiopathic PD[5][6].

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

AGPI2

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Agyany Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agyany Pharma.

Explore the full profile